IMM47 / ImmuneOnco Biopharma - LARVOL DELTA

Humanized Monoclonal Antibody IMM47, Targeting CD24, Exhibits Exceptional Anti-Tumor Efficacy By Blocking the CD24/Siglec-10 Interaction and Can be Used As Monotherapy or in Combination with Anti-PD1 Antibodies for Cancer Immunotherapy (ASH 2023) - "IMM47 monotherapy or in combination with SIRP-Fc fusion protein (IMM01) or anti-PD-1 antibodies were used to test IMM47's anti-tumor efficacy in SCID mice with Jeko-1 or MCF-7 tumor cell xenotransplantation and hPD-1 Tg C57BL/6 mice with MC38-hCD24/hPD-L1 tumor cell homologous transplantation models...Additionally, an in vivo pharmacodynamics assay of IMM47 in combination with different PD-1 antibodies revealed that IMM47 exhibits synergistic therapeutic efficacy when combined with Tislelizumab, Opdivo, and Keytruda. Our research showed that the humanized anti-CD24 mAb IMM47 had excellent anti-tumor effect. The extracellular domain's N-glycosylation alteration has no effect on IMM47's ability to bind to CD24. The in vitro assays revealed that IMM47 exhibits significant ADCC, ADCP, ADCT, and CDC activities."

Clinical • Combination therapy • IO biomarker • Monotherapy • Oncology • Transplantation • CD24 • PD-L1 • SIRPA

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy. (PubMed, Antib Ther) - "IMM47 also has powerful synergistic therapeutic efficacy when combined with Tislelizumab, Opdivo and Keytruda, by blocking CD24/Siglec-10 interaction through macrophage antigen presentation with strong ADCC, ADCP, ADCT and CDC activities and with a safe profile. IMM47 binding to CD24 is independent of N-glycosylation modification of the extracellular domain."

Combination therapy • Journal • Monotherapy • Oncology • Transplantation • CD24

A Study Of IMM47 In Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor • CD24 • PD-L1

'New Stock Performance' Immune Onco (01541.HK) opened 14% higher at 21.2 yuan [Google translation] (Yahoo Finance) - "It is expected that the net proceeds raised will be approximately 235 million yuan, of which approximately 40% and 28% will be used for the core product IMM01 respectively., as well as ongoing and planned clinical trials, preparation for registration applications and planned commercial launch of core products IMM0306, IMM2902 and IMM2520; approximately 10% will be used for planned clinical trials of IMM47 (CD24 monoclonal antibody)."

Commercial • Oncology

A Study Of IMM47 In Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Metastases • New P1 trial • Oncology • Solid Tumor • CD24 • PD-L1

Preclinical development of a monoclonal antibody targeting CD24 as cancer immunotherapy (AACR 2023) - "Our data has also confirmed that IMM47 specifically binds to and induces ADCC (antibody-dependent cellular cytotoxicity) ,ADCP (antibody-dependent cellular phagocytosis), and CDC (complement-dependent cytotoxicity) against a variety of cancer cells. Taken together, our data show that targeting CD24 on tumor cells using our IMM47 antibody may serve as potent immunotherapy for multiple cancer indications."

IO biomarker • Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor • CD24